doi:10.23750/abm.v88i1.6048 Talebi S, Ghaedi E, Sadeghi E, et al
Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3- methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl] thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
Clinical superiority must be assessed through direct trials examining weight change, metabolic outcomes, adverse events, discontinuation rates and longer-term safety
Espino says shes always experienced her weight as a difficult-to-manage chronic disease, and she sees GLP-1 as a pragmatic approach to a long-standing problem
Medicare Part D launched the GLP-1 Bridge program on July 1, 2026, covering Wegovy (injection and tablet), Zepbound (KwikPen only), and Foundayo for weight management at $50/month through December 31, 2027
doi: 10.1080/14656566.2018.1509955 31 GrecoD